Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Revenue: 2021-2024

Historic Revenue for Tarsus Pharmaceuticals (TARS) over the last 4 years, with Dec 2024 value amounting to $183.0 million.

  • Tarsus Pharmaceuticals' Revenue rose 146.68% to $118.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $366.1 million, marking a year-over-year increase of 182.44%. This contributed to the annual value of $183.0 million for FY2024, which is 948.62% up from last year.
  • As of FY2024, Tarsus Pharmaceuticals' Revenue stood at $183.0 million, which was up 948.62% from $17.4 million recorded in FY2023.
  • Over the past 5 years, Tarsus Pharmaceuticals' Revenue peaked at $183.0 million during FY2024, and registered a low of $17.4 million during FY2023.
  • In the last 3 years, Tarsus Pharmaceuticals' Revenue had a median value of $25.8 million in 2022 and averaged $75.4 million.
  • In the last 5 years, Tarsus Pharmaceuticals' Revenue slumped by 54.73% in 2022 and then skyrocketed by 948.62% in 2024.
  • Tarsus Pharmaceuticals' Revenue (Yearly) stood at $57.0 million in 2021, then plummeted by 54.73% to $25.8 million in 2022, then plummeted by 32.42% to $17.4 million in 2023, then spiked by 948.62% to $183.0 million in 2024.